SCHEMBL1341114

SCHEMBL1341114

COc1ccc(NC(=O)Nc2nc(CC(=O)O)c(S(=O)(=O)c3ccccn3)s2)c(C(=O)C2CCCC2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.39
MAPT P10636 4/20 0.36
GRM4 Q14833 2/20 0.36
RAB9A P51151 4/20 0.36
NPC1 O15118 3/20 0.36
MEN1 O00255 3/20 0.36
POLB P06746 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
GCK P35557 1/20 0.36
ALDH1A1 P00352 3/20 0.35
HTT P42858 2/20 0.35
KDM4E B2RXH2 2/20 0.35
MCL1 Q07820 1/20 0.35
ITK Q08881 1/20 0.35
RORC P51449 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1341812 0.90 GRM4 (0.36) MAPTGRM4RAB9ANPC1SMN1; SMN2
SCHEMBL1341198 0.90 KMT2A (0.37) KMT2AMAPTGRM4RAB9ANPC1
SCHEMBL1341795 0.90 KMT2A (0.40) KMT2AMAPTGRM4RAB9ANPC1
SCHEMBL1338714 0.89 GRM4 (0.36) GRM4RAB9AALDH1A1KDM4ERORC
SCHEMBL1341820 0.89 KMT2A (0.39) KMT2AMAPTGRM4RAB9ANPC1
SCHEMBL1342944 0.89 GRM4 (0.38) KMT2AMAPTGRM4RAB9ANPC1
SCHEMBL1339934 0.89 PTGDR2 (0.39) KMT2AMAPTGRM4RAB9ANPC1
SCHEMBL1340258 0.88 MAPT (0.34) KMT2AMAPTGRM4MEN1LMNA
SCHEMBL1340268 0.88 MAPT (0.41) KMT2AMAPTRAB9ANPC1MEN1
SCHEMBL1342389 0.88 MAPT (0.37) KMT2AMAPTRAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 KMT2A 1526/4885MAPT 2678/4885GRM4 2551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.